Holen Sie sich die Stockscreener-App
2.67
16.04%
-0.51
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Context Therapeutics (NASDAQ:CNTX) and Clearmind Medicine (NASDAQ:CMND) Head-To-Head Contrast - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Context Therapeutics (NASDAQ:CNTX) Given Buy Rating at D. Boral Capital - Defense World
Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Price Target Raised to $7.00 - MarketBeat
Context Therapeutics Reports Full Year 2025 Operating and Financial Results - National Today
According to the latest financial data, biopharmaceutical company Context Therapeutics Inc. (Context Therapeutics) held total cash and cash equivalents of $66 million as of December 31, 2025. - Bitget
Context Therapeutics Highlights Evolving T Cell Engager Pipeline - TipRanks
Context Therapeutics (NASDAQ:CNTX) Issues Earnings Results - MarketBeat
Context Therapeutics Reports Full Year 2025 Operating And Financial Results - TradingView
Context Therapeutics Inc. Reports Financial Results and Upcoming Milestones for CTIM-76 and CT-95 Trials - Quiver Quantitative
Context updates corporate presentation, flags interim CTIM-76/CT-95/CT-202 milestones; cash runway into mid-2027 - TradingView
Context Therapeutics (NASDAQ: CNTX) outlines T‑cell engager trials and cash runway - Stock Titan
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) EstimateContext Therapeutics (NASDAQ:CNTX) - Benzinga
With $66M left, Context targets 2 cancer trial updates in 2026 - Stock Titan
CNTX: Net loss rose to $36.1M in 2025; $66M cash funds operations into mid-2027, more capital needed - TradingView
Context Therapeutics (NASDAQ: CNTX) advances three T cell engager programs - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Surprises Report: How does Bausch Health Companies Inc perform in inflationary periods2026 Key Lessons & Daily Stock Momentum Reports - baoquankhu1.vn
Context Therapeutics to Present Poster at AACR Annual Meeting - National Today
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 - The Manila Times
Loss Report: Is Context Therapeutics Inc stock risky to hold now2026 Dividend Review & Expert Curated Trade Ideas - baoquankhu1.vn
HR Positive/ HER2 Negative Breast Cancer Clinical Trial - openPR.com
HR Positive/ HER2 Negative Breast Cancer Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart
CNTX PE Ratio & Valuation, Is CNTX Overvalued - Intellectia AI
H.C. Wainwright Maintains Buy on APRE Aprea Therapeutics Inc March 2026 - Meyka
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data - MarketBeat
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - MSN
Context Therapeutics Inc. Files 8-K and Certificate of Correction to Amended and Restated Certificate of Incorporation (March 11, 2026) - Minichart
Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes - TipRanks
Board terms change at Context Therapeutics (NASDAQ: CNTX) after court ruling - Stock Titan
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
Quarterly Earnings: How does Context Therapeutics Inc compare to its peersWeekly Profit Report & Risk Controlled Swing Alerts - baoquankhu1.vn
Context Therapeutics (CNTX) to Release Earnings on Thursday - Defense World
Movement Recap: Can Context Therapeutics Inc stock double in the next yearPortfolio Update Report & Stock Market Timing Techniques - baoquankhu1.vn
HER2-Negative Metastatic Breast Cancer Market Expected - openPR.com
HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene - StreetInsider
Context Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ADXN.SW Addex Therapeutics Ltd (SIX) 09 Mar 2026: Earnings due; liquidity and forecast to watch - Meyka
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference - MarketBeat
A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance - Sahm
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
New Canadian Biotech 26therapeutics Inc. Targets Root Cause of Dry Eye Disease with First-in-Class Therapy - Cantech Letter
CNTX SEC FilingsContext Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
CNTX: Advancing three T-cell engager programs in solid tumors with key data milestones ahead - TradingView
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
CNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CNTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Sell - MarketBeat
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections - The Globe and Mail
CNTX Should I Buy - Intellectia AI
Context Therapeutics (NASDAQ: CNTX) targets annual director elections in governance shift - Stock Titan
Equities Analysts Issue Forecasts for CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX FY2025 Earnings - MarketBeat
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Lifesci Capital - Defense World
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):